Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main focus: Genomic medicines for ocular diseases
Company stage: Pre-clinical
Diseases (gene editing): Undisclosed
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: Paris, France
Partners: Intellia Therapeutics
SparingVision is a gene therapy focused company, that develops medicines for the treatment of ocular diseases. The company is currently developing multiple pre-clinical programmes, however, the company's engagement in gene editing comes through recent collaboration with Intellia Therapeutics. As part of the collaboration, SparingVision has been granted a licence to develop medicines for up to three ocular targets. Furthermore, the companies will together develop AAV vectors and LNP-based approaches to address delivery of CRISPR-Cas9 genome-editing reagents to the retina.